Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402 · clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
80
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer